1
|
Gauglitz GG, Korting HC, Pavicic T,
Ruzicka T and Jeschke MG: Hypertrophic scarring and keloids:
pathomechanisms and current and emerging treatment strategies. Mol
Med. 17:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jun JI and Lau LF: Taking aim at the
extracellular matrix: CCN proteins as emerging therapeutic targets.
Nat Rev Drug Discov. 10:945–963. 2011. View
Article : Google Scholar : PubMed/NCBI
|
3
|
Shi-Wen X, Leask A and Abraham D:
Regulation and function of connective tissue growth factor/CCN2 in
tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev.
19:133–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
de Winter P, Leoni P and Abraham D:
Connective tissue growth factor: structure-function relationships
of a mosaic, multifunctional protein. Growth Factors. 26:80–91.
2008.PubMed/NCBI
|
5
|
Chen CC and Lau LF: Functions and
mechanisms of action of CCN matricellular proteins. Int J Biochem
Cell Biol. 41:771–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Phanish MK, Winn SK and Dockrell ME:
Connective tissue growth factor-(CTGF, CCN2) - a marker, mediator
and therapeutic target for renal fibrosis. Nephron Exp Nephrol.
114:e83–e92. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hu X, Wang H, Liu J, Fang X, Tao K, Wang
Y, Li N, Shi J, Wang Y, Ji P, Cai W, Bai X, Zhu X, Han J and Hu D:
The role of ERK and JNK signaling in connective tissue growth
factor induced extracellular matrix protein production and scar
formation. Arch Dermatol Res. 305:433–445. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shi-wen X, Stanton LA, Kennedy L, Pala D,
Chen Y, Howat SL, Renzoni EA, Carter DE, Bou-Gharios G, Stratton
RJ, Pearson JD, Beier F, Lyons KM, Black CM, Abraham DJ and Leask
A: CCN2 is necessary for adhesive responses to transforming growth
factor-beta1 in embryonic fibroblasts. J Biol Chem.
281:10715–10726. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Colwell AS, Phan TT, Kong W, Longaker MT
and Lorenz PH: Hypertrophic scar fibroblasts have increased
connective tissue growth factor expression after transforming
growth factor-beta stimulation. Plast Reconstr Surg. 116:1387–1390.
2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
van der Veer WM, Bloemen MC, Ulrich MM,
Molema G, van Zuijlen PP, Middelkoop E and Niessen FB: Potential
cellular and molecular causes of hypertrophic scar formation.
Burns. 35:15–29. 2009.PubMed/NCBI
|
11
|
Wang J, Dodd C, Shankowsky HA, Scott PG
and Tredget EE: Wound healing research group: Deep dermal
fibroblasts contribute to hypertrophic scarring. Lab Invest.
88:1278–1290. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nakerakanti SS, Bujor AM and Trojanowska
M: CCN2 is required for the TGF-β induced activation of
Smad1-Erk1/2 signaling network. PLoS One. 6:e219112011.
|
13
|
Sisco M, Kryger ZB, O’Shaughnessy KD, Kim
PS, Schultz GS, Ding XZ, Roy NK, Dean NM and Mustoe TA: Antisense
inhibition of connective tissue growth factor (CCN2/CCN2) mRNA
limits hypertrophic scarring without affecting wound healing in
vivo. Wound Repair Regen. 16:661–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Scaffidi AK, Petrovic N, Moodley YP,
Fogel-Petrovic M, Kroeger KM, Seeber RM, Eidne KA, Thompson PJ and
Knight DA: alpha(v)beta(3) integrin interacts with the transforming
growth factor beta (TGFbeta) type II receptor to potentiate the
proliferative effects of TGFbeta1 in living human lung fibroblasts.
J Biol Chem. 279:37726–37733. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Asano Y, Ihn H, Yamane K, Jinnin M, Mimura
Y and Tamaki K: Increased expression of integrin alpha(v)beta3
contributes to the establishment of autocrine TGF-beta signaling in
scleroderma fibroblasts. J Immunol. 175:7708–7718. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Cruet-Hennequart S, Maubant S, Luis J,
Gauduchon P, Staedel C and Dedhar S: Alpha(v) integrins regulate
cell proliferation through integrin-linked kinase (ILK) in ovarian
cancer cells. Oncogene. 22:1688–1702. 2003. View Article : Google Scholar : PubMed/NCBI
|
17
|
Levinson H, Hopper JE and Ehrlich HP:
Overexpression of integrin alphav promotes human osteosarcoma cell
populated collagen lattice contraction and cell migration. J Cell
Physiol. 193:219–224. 2002. View Article : Google Scholar : PubMed/NCBI
|
18
|
Meerovitch K, Bergeron F, Leblond L,
Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T and
Attardo G: A novel RGD antagonist that targets both alphavbeta3 and
alpha5beta1 induces apoptosis of angiogenic endothelial cells on
type I collagen. Vascul Pharmacol. 40:77–89. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Trusolino L, Serini G, Cecchini G, Besati
C, Ambesi-Impiombato FS, Marchisio PC and De Filippi R: Growth
factor-dependent activation of alphavbeta3 integrin in normal
epithelial cells: implications for tumor invasion. J Cell Biol.
142:1145–1156. 1998. View Article : Google Scholar
|
20
|
Liu J, Wang Y, Pan Q, Su Y, Zhang Z, Han
J, Zhu X, Tang C and Hu D: Wnt/β-catenin pathway forms a negative
feedback loop during TGF-β1 induced human normal skin
fibroblast-to-myofibroblast transition. J Dermatol Sci. 65:38–49.
2012.
|
21
|
Shi JH, Guan H, Shi S, Cai WX, Bai XZ, Hu
XL, Fang XB, Liu JQ, Tao K, Zhu XX, Tang CW and Hu DH: Protection
against TGF-β1-induced fibrosis effects of IL-10 on dermal
fibroblasts and its potential therapeutics for the reduction of
skin scarring. Arch Dermatol Res. 305:341–52. 2013.
|
22
|
Bell E, Ivarsson B and Merrill C:
Production of a tissue-like structure by contraction of collagen
lattices by human fibroblasts of different proliferative potential
in vitro. Proc Natl Acad Sci USA. 76:1274–1278. 1979. View Article : Google Scholar : PubMed/NCBI
|
23
|
Sarrazy V, Billet F, Micallef L, Coulomb B
and Desmoulière A: Mechanisms of pathological scarring: role of
myofibroblasts and current developments. Wound Repair Regen.
19(Suppl 1): s10–s15. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gurtner GC, Werner S, Barrandon Y and
Longaker MT: Wound repair and regeneration. Nature. 453:314–21.
2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Leask A and Abraham DJ: All in the CCN
family: essential matricellular signaling modulators emerge from
the bunker. J Cell Sci. 119:4803–4810. 2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Luft FC: CCN2, the connective tissue
growth factor. J Mol Med (Berl). 86:1–3. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang Q, Usinger W, Nichols B, Gray J, Xu
L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, Lin A and
Yeowell D: Cooperative interaction of CCN2 and TGF-β in animal
models of fibrotic disease. Fibrogenesis Tissue Repair.
4:42011.
|
28
|
Leask A and Abraham DJ: The role of
connective tissue growth factor, a multifunctional matricellular
protein, in fibroblast biology. Biochem Cell Biol. 81:355–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Blom IE, Goldschmeding R and Leask A: Gene
regulation of connective tissue growth factor: new targets for
antifibrotic therapy? Matrix Biol. 21:473–482. 2002. View Article : Google Scholar : PubMed/NCBI
|
30
|
Igarashi A, Okochi H, Bradham DM and
Grotendorst GR: Regulation of connective tissue growth factor gene
expression in human skin fibroblasts and during wound repair. Mol
Biol Cell. 4:637–645. 1993. View Article : Google Scholar : PubMed/NCBI
|
31
|
Mori T, Kawara S, Shinozaki M, Hayashi N,
Kakinuma T, Igarashi A, Takigawa M, Nakanishi T and Takehara K:
Role and interaction of connective tissue growth factor with
transforming growth factor-beta in persistent fibrosis: a mouse
fibrosis model. J Cell Physiol. 181:153–159. 1999. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ihn H, Yamane K, Kubo M and Tamaki K:
Blockade of endogenous transforming growth factor beta signaling
prevents up-regulated collagen synthesis in scleroderma
fibroblasts: association with increased expression of transforming
growth factor beta receptors. Arthritis Rheum. 44:474–480. 2001.
View Article : Google Scholar
|
33
|
Miller WH, Keenan RM, Willette RN and Lark
MW: Identification and in vivo efficacy of small-molecule
antagonists of integrin alphavbeta3 (the vitronectin receptor).
Drug Discov Today. 5:397–408. 2000. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gao R and Brigstock DR: Connective tissue
growth factor (CCN2) induces adhesion of rat activated hepatic
stellate cells by binding of its C-terminal domain to integrin
alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem.
279:8848–8855. 2004. View Article : Google Scholar
|
35
|
Blaschuk KL, Guérin C and Holland PC:
Myoblast alphav beta3 integrin levels are controlled by
transcriptional regulation of expression of the beta3 subunit and
down-regulation of beta3 subunit expression is required for
skeletal muscle cell differentiation. Dev Biol. 184:266–277. 1997.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Milner R, Huang X, Wu J, Nishimura S,
Pytela R, Sheppard D and ffrench-Constant C: Distinct roles for
astrocyte alphavbeta5 and alphavbeta8 integrins in adhesion and
migration. J Cell Sci. 112:4271–4279. 1999.PubMed/NCBI
|
37
|
Rodan SB and Rodan GA: Integrin function
in osteoclasts. J Endocrinol. 154:S47–S56. 1997.PubMed/NCBI
|
38
|
Thomas GJ, Lewis MP, Hart IR, Marshall JF
and Speight PM: AlphaVbeta6 integrin promotes invasion of squamous
carcinoma cells through up-regulation of matrix
metalloproteinase-9. Int J Cancer. 92:641–650. 2001. View Article : Google Scholar : PubMed/NCBI
|
39
|
Asano Y, Ihn H, Yamane K, Jinnin M and
Tamaki K: Increased expression of integrin alphavbeta5 induces the
myofibroblastic differentiation of dermal fibroblasts. Am J Pathol.
168:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
|